C
Calyxo
An innovation-driven medical device company focused on improving care for patients with kidney stones, a common and painful condition that consumes vast amounts of healthcare resources today
About Calyxo
Calyxo, Inc. specializes in developing cutting-edge medical devices aimed at revolutionizing the treatment of kidney stones. Founded in February 2016 in collaboration with leading U.S. urologists, the company addresses the significant clinical needs in the field of urology. Calyxo's core mission is to improve patient care by providing innovative solutions that enable urologists to achieve superior clinical outcomes safely and efficiently. The company operates in the medical device market, specifically targeting healthcare providers and urology specialists. Its business model revolves around the development, commercialization, and sale of advanced medical devices designed to treat kidney stones more effectively. Revenue is generated through the sale of these devices to hospitals, clinics, and medical professionals. The leadership team at Calyxo brings extensive experience in medical device startups, product development, and commercial launch, ensuring a strong foundation for the company's growth and success.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Pleasanton, United States
- Employees
- 340
- Open positions
- 27
- Dealroom signal
- 93.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Spinout, urinary, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES FOther financing | Apr 2026 | $40M | $250M | Questa Capital Management · CRG LP · Janus Henderson Investors · Avidity Partners | ↗ |
| SERIES DOther financing | Dec 2023 | $50M | $200M | Questa Capital Management · CRG LP · Avidity Partners | ↗ |
Growth signals
Latest recorded traffic for Calyxo is 3.7K monthly website visits, down 28.8% over the last three months. Calyxo's team grew 18.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Questa Capital Management- CLCRG LP
Avidity Partners
Janus Henderson Investors
Ally Bridge Group
Other known investors1 additional known investor
Massachusetts General Hospital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Calyxo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Calyxo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.